Focus Partners Wealth
VRTX icon

Focus Partners Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

Focus Partners Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$64.1M Sell
128,958
-2,477
-2% -$1.1M 0.07% 268
2026
Q1 		$58.7M Sell
131,435
-1,411
-1% -$658K 0.07% 260
2025
Q4 		$60.2M Sell
132,846
-6,369
-5% -$2.75M 0.07% 252
2025
Q3 		$54.5M Sell
139,215
-3,894
-3% -$1.63M 0.09% 204
2025
Q2 		$63.7M Sell
143,109
-96
-0.1% -$44.2K 0.14% 150
2025
Q1 		$69.4M Buy
143,205
+2,093
+1% +$975K 0.17% 127
2024
Q4 		$56.8M Buy
141,112
+18,187
+15% +$8.43M 0.15% 139
2024
Q3 		$57.2M Buy
122,925
+1,324
+1% +$636K 0.18% 118
2024
Q2 		$57M Buy
121,601
+3,124
+3% +$1.36M 0.19% 123
2024
Q1 		$49.5M Buy
118,477
+10,377
+10% +$4.39M 0.4% 56
2023
Q4 		$44M Buy
+108,100
New +$39.9M 0.58% 35

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Focus Partners Wealth's VRTX Position: Q2 2026 in Review

Focus Partners Wealth reduced its Vertex Pharmaceuticals (VRTX) stake by 1.9% in Q2 2026, selling an estimated $1.1M and leaving 128,958 shares worth $64.1M. The position accounts for 0.07% of the portfolio, ranked #268.

Focus Partners Wealth first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $69.4M in Q1 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Focus Partners Wealth held 128,958 shares of Vertex Pharmaceuticals worth $64.1M as of Q2 2026.
  • Focus Partners Wealth sold 2,477 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.1M.
  • Vertex Pharmaceuticals made up 0.07% of Focus Partners Wealth's portfolio in Q2 2026, its #268 holding.
  • Focus Partners Wealth first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Focus Partners Wealth's Vertex Pharmaceuticals position peaked at $69.4M in Q1 2025.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.